Vaccines have saved millions of lives, but nobody likes getting a shot. That’s why scientists are trying to develop oral vaccines for infectious diseases.
But to be effective, the vaccine must survive digestion and reach immune cells within the intestinal wall. Now, researchers reporting in the ACS journal Nano Letters have developed oral vaccines powered by micromotors that target the mucus layer of the intestine.
In addition to avoiding needles, oral vaccines can generate a broader immune response by stimulating immune cells within the mucus layer of the intestine to produce a special class of antibody called immunoglobulin A (IgA). Joseph Wang, Liangfang Zhang and colleagues wondered if they could use magnesium particles as tiny motors to deliver an oral vaccine against the bacterial pathogen Staphylococcus aureus. When coated over most of their surfaces with titanium dioxide, magnesium microparticles use water as fuel to generate hydrogen bubbles that power their propulsion.
To develop the oral vaccine, the researchers coated magnesium micromotors with red blood cell membranes that displayed the Staphylococcal ?-toxin, along with a layer of chitosan to help them stick to the intestinal mucus. Then, they added an enteric coating that protects drugs from the acidic conditions of the stomach. When given orally to mice, the micromotors safely passed through the stomach, and then the enteric coating dissolved, activating the motors. Imaging of mice that had been given the vaccine showed that the micromotors accumulated in the intestinal wall much better than non-motorized particles. The micromotors also stimulated the production of about ten times more IgA antibodies against the Staphylococcal ?-toxin than the static particles.
Learn more: Micromotors deliver oral vaccines
The Latest on: Oral vaccines
via Google News
The Latest on: Oral vaccines
- CDC: Severe allergic reactions to COVID-19 vaccine are rareon January 24, 2021 at 4:18 am
You may have heard the virus isn't safe and the side effects are horrible, but doctors say the benefits of the vaccine outweigh the risk of the virus.
- Canadian dentists push for clarity about vaccine priority: ‘We’re doctors too’on January 24, 2021 at 4:00 am
Everybody else's patients are in masks. Ours aren't,' one dentist said of the risk of the job amid the coronavirus pandemic.
- In Crises, Vaccines Can Be Stretched, but Not Easilyon January 23, 2021 at 9:01 am
Shortages of shots for yellow fever, polio and other diseases have led to innovative solutions even in very poor countries.
- COVID-19 vaccine guidance for those who are lactating is based on faulty assumptions, experts sayon January 22, 2021 at 2:27 pm
Guidelines have grouped breastfeeding and pregnant people together when addressing vaccine safety. That, experts say, doesn't make sense.
- Key Capital COVID-19 Oral Pill Vaccine Records 90% Reduction in Virus Infectivity in Early Studyon January 18, 2021 at 2:20 pm
Promising Safety Profile and 90% Reduction in Virus Infectivity Reported for Key Capital COVID-19 Oral Pill Therapeutic Vaccine. NEW YORK, NY / ACCESSWIRE / January 18, 2021 / KEY ...
- iosBio signs exclusive worldwide licensing agreement granting ImmunityBio rights to OraPro(TM) oral vaccine platform technology for COVID-19on January 12, 2021 at 2:15 pm
Bio signs exclusive worldwide licensing agreement granting ImmunityBio rights to OraPro (TM) oral vaccine platform technology for COVID-19 iosBio licenses its OraPro TM thermal stabilization ...
- Oral Vaccines Market is in huge demand | Merck, GSK, Sanofion January 12, 2021 at 10:05 am
Global Oral Vaccines Market Report 2020, Covid 19 Outbreak Impact research report added by Report Ocean, is an in-depth analysis of market characteristics, size and growth, segmentation, regional and ...
- Oral COVID-19 vaccine beckons, as ImmunityBio licenses iosBio techon January 12, 2021 at 8:30 am
ImmunityBio has licensed technology underpinning a COVID-19 vaccine that could be administered orally rather than by injection from UK biotech iosBio. Approvals for injectable vaccines for COVID-19 ...
- iosBio signs exclusive worldwide licensing agreement granting ImmunityBio rights to OraPro™ oral vaccine platform technology for COVID-19 | Morningstaron January 12, 2021 at 3:56 am
Bio signs exclusive worldwide licensing agreement granting ImmunityBio rights to OraPro™ oral vaccine platform technology for COVID-19. iosBio licenses its Ora ...
- Cholera Vaccine (Oral Route) Market Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts to 2026on January 11, 2021 at 4:03 pm
Final Report will add the analysis of the impact of COVID-19 on this industry." Global "Cholera Vaccine (Oral Route) Market" report provides key analysis on the market status of Cholera Vaccine (Oral ...
via Bing News